This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/bridgebio-stock-dwarfism-drug-biomarin-40cc3e70
- Order Reprints
- Print Article
BridgeBio Pharma stock was soaring after the biopharmaceutical company reported positive results in a Phase two clinical trial for an experimental treatment for achondroplasia, the most common type of short-limbed dwarfism.
On Monday, BridgeBio (ticker: BBIO) said in a news release that its experimental drug Infigratinib showed an annualized improvement of 3.03 centimeters in so-called height velocity, or gains in height, in a study including 10 children.